Literature DB >> 21051595

Frequent mutation of BAP1 in metastasizing uveal melanomas.

J William Harbour1, Michael D Onken, Elisha D O Roberson, Shenghui Duan, Li Cao, Lori A Worley, M Laurin Council, Katie A Matatall, Cynthia Helms, Anne M Bowcock.   

Abstract

Metastasis is a defining feature of malignant tumors and is the most common cause of cancer-related death, yet the genetics of metastasis are poorly understood. We used exome capture coupled with massively parallel sequencing to search for metastasis-related mutations in highly metastatic uveal melanomas of the eye. Inactivating somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (BAP1) on chromosome 3p21.1 in 26 of 31 (84%) metastasizing tumors, including 15 mutations causing premature protein termination and 5 affecting its ubiquitin carboxyl-terminal hydrolase domain. One tumor harbored a frameshift mutation that was germline in origin, thus representing a susceptibility allele. These findings implicate loss of BAP1 in uveal melanoma metastasis and suggest that the BAP1 pathway may be a valuable therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051595      PMCID: PMC3087380          DOI: 10.1126/science.1194472

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  21 in total

1.  The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology.

Authors:  Paul T Finger
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

2.  Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB.

Authors:  Johanna C Scheuermann; Andrés Gaytán de Ayala Alonso; Katarzyna Oktaba; Nga Ly-Hartig; Robert K McGinty; Sven Fraterman; Matthias Wilm; Tom W Muir; Jürg Müller
Journal:  Nature       Date:  2010-05-02       Impact factor: 49.962

3.  Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death.

Authors:  Michael D Onken; Lori A Worley; Justis P Ehlers; J William Harbour
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

4.  An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Tuscan; J William Harbour
Journal:  J Mol Diagn       Date:  2010-04-22       Impact factor: 5.568

5.  Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1.

Authors:  Shahram Misaghi; Søren Ottosen; Anita Izrael-Tomasevic; David Arnott; Mohamed Lamkanfi; James Lee; Jinfeng Liu; Karen O'Rourke; Vishva M Dixit; Angus C Wilson
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

6.  BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.

Authors:  Hiroyuki Nishikawa; Wenwen Wu; Ayaka Koike; Ryoko Kojima; Hiromichi Gomi; Mamoru Fukuda; Tomohiko Ohta
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

7.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

8.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.

Authors:  Catherine D Van Raamsdonk; Vladimir Bezrookove; Gary Green; Jürgen Bauer; Lona Gaugler; Joan M O'Brien; Elizabeth M Simpson; Gregory S Barsh; Boris C Bastian
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

9.  Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma.

Authors:  J Bauer; E Kilic; J Vaarwater; B C Bastian; C Garbe; A de Klein
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

10.  Exome sequencing identifies the cause of a mendelian disorder.

Authors:  Sarah B Ng; Kati J Buckingham; Choli Lee; Abigail W Bigham; Holly K Tabor; Karin M Dent; Chad D Huff; Paul T Shannon; Ethylin Wang Jabs; Deborah A Nickerson; Jay Shendure; Michael J Bamshad
Journal:  Nat Genet       Date:  2009-11-13       Impact factor: 38.330

View more
  518 in total

Review 1.  Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Authors:  Sebastian Walpole; Antonia L Pritchard; Colleen M Cebulla; Robert Pilarski; Meredith Stautberg; Frederick H Davidorf; Arnaud de la Fouchardière; Odile Cabaret; Lisa Golmard; Dominique Stoppa-Lyonnet; Erin Garfield; Ching-Ni Njauw; Mitchell Cheung; Joni A Turunen; Pauliina Repo; Reetta-Stiina Järvinen; Remco van Doorn; Martine J Jager; Gregorius P M Luyten; Marina Marinkovic; Cindy Chau; Miriam Potrony; Veronica Höiom; Hildur Helgadottir; Lorenza Pastorino; William Bruno; Virginia Andreotti; Bruna Dalmasso; Giulia Ciccarese; Paola Queirolo; Luca Mastracci; Karin Wadt; Jens Folke Kiilgaard; Michael R Speicher; Natasha van Poppelen; Emine Kilic; Rana'a T Al-Jamal; Irma Dianzani; Marta Betti; Carsten Bergmann; Sandro Santagata; Sonika Dahiya; Saleem Taibjee; Jo Burke; Nicola Poplawski; Sally J O'Shea; Julia Newton-Bishop; Julian Adlard; David J Adams; Anne-Marie Lane; Ivana Kim; Sonja Klebe; Hilary Racher; J William Harbour; Michael L Nickerson; Rajmohan Murali; Jane M Palmer; Madeleine Howlie; Judith Symmons; Hayley Hamilton; Sunil Warrier; William Glasson; Peter Johansson; Carla Daniela Robles-Espinoza; Raul Ossio; Annelies de Klein; Susana Puig; Paola Ghiorzo; Maartje Nielsen; Tero T Kivelä; Hensin Tsao; Joseph R Testa; Pedram Gerami; Marc-Henri Stern; Brigitte Bressac-de Paillerets; Mohamed H Abdel-Rahman; Nicholas K Hayward
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

2.  Multiplexed array-based and in-solution genomic enrichment for flexible and cost-effective targeted next-generation sequencing.

Authors:  Magdalena Harakalova; Michal Mokry; Barbara Hrdlickova; Ivo Renkens; Karen Duran; Henk van Roekel; Nico Lansu; Mark van Roosmalen; Ewart de Bruijn; Isaac J Nijman; Wigard P Kloosterman; Edwin Cuppen
Journal:  Nat Protoc       Date:  2011-11-03       Impact factor: 13.491

Review 3.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 4.  New strategies in melanoma: molecular testing in advanced disease.

Authors:  Scott E Woodman; Alexander J Lazar; Kenneth D Aldape; Michael A Davies
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

Review 5.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

Review 6.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

7.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Authors:  A Ari Hakimi; Ying-Bei Chen; James Wren; Mithat Gonen; Omar Abdel-Wahab; Adriana Heguy; Han Liu; Shugaku Takeda; Satish K Tickoo; Victor E Reuter; Martin H Voss; Robert J Motzer; Jonathan A Coleman; Emily H Cheng; Paul Russo; James J Hsieh
Journal:  Eur Urol       Date:  2012-09-27       Impact factor: 20.096

Review 8.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

9.  BAP1 is phosphorylated at serine 592 in S-phase following DNA damage.

Authors:  Ziad M Eletr; Luming Yin; Keith D Wilkinson
Journal:  FEBS Lett       Date:  2013-11-05       Impact factor: 4.124

Review 10.  Targeted therapies in melanoma.

Authors:  Stergios J Moschos; Ramya Pinnamaneni
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.